ATYR Stock In Focus After FDA Alignment On Efzofitimod Phase 3

aTyr Pharma announced FDA alignment on the protocol for a global Phase 3 trial of efzofitimod in chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. The regulatory agreement clears an important development milestone and supports progression of the company’s lead clinical program, with potential to move ATYR shares materially.